A company's CEO wants to commercially promote a device under an IDE study. This plan:
A Phase I study of a new blood pressure medication has been submitted for initial approval to an IRB/IEC. In accordance with the CFR, the IRB/IEC must consider which of the following criteria when determining whether to approve the study?
Which of the following statements about the initial IND application submission by a sponsor to the U.S. Food and Drug Administration is correct?
Sponsor must maintain drug disposition records for how long after marketing approval?
According to the CFR, when children who are wards of the state are enrolled into a clinical trial, what is required?
